Tuesday, April 21, 2009

Despite advances in biomedical sciences, the flow of new drugs is slowing to a trickle.

  • Coporate policies discourage innovation
  • Mega mergers, i.e. Pfizer/Wyeth, Merck & Co/Schering-Plough and Roche/Genentech in 2009
  • Over-dependence on blockbuster drugs
  • Concentration on marketing over R&D

See "Drug discovery in jeopardy" from The Journal of Clinical Investigation



Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Followers